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Abstract
Background—Blockade of platelet activation and aggregation can inhibit metastasis in
preclinical models and is associated with cancer prevention. To test whether disruption of platelet
function with clopidogrel and aspirin would decrease the number of circulating tumor cells
(CTCs) in patients with metastatic breast cancer, a randomized phase II study was performed.
Methods—Patients with metastatic breast cancer who were not currently receiving cytotoxic
chemotherapy were eligible. Patients were randomized to receive either clopidogrel and aspirin or
to a control group receiving no treatment. Phlebotomy was performed at baseline, at 2 and 4
weeks, and monthly thereafter to obtain specimens to assess CTC, platelet aggregation, and
thrombin activity. The primary end point was the proportion of patients with detectable CTCs at 1
month.
Results—Forty-eight patients were enrolled and 42 were evaluable at 1 month. Baseline CTC
numbers were ≥ 5 in 13% and ≥ 1 in 65% of patients. Despite adequate platelet function inhibition
in the treatment group, the proportion of patients with detectable CTCs was similar between the
clopidogrel/aspirin and control groups at baseline (P = .21) and 4 weeks (P = .75), showing no
treatment effect. Measured endogenous thrombin potential did not correlate with CTC number. No
bleeding-related serious adverse events (SAEs) occurred.
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Conclusion—The baseline CTC numbers were lower than expected, decreasing the ability to
detect an impact of platelet inhibition on CTCs. Clopidogrel and aspirin were well tolerated.
Future studies evaluating the potential therapeutic role of antiplatelet therapy in breast cancer
remain of interest, and they may be informed by these results.
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Introduction
The metastatic process is complex and involves migration from the primary tumor site,
vascular invasion, evasion of host immune defenses, dissemination (often as microemboli
with tumor cells, platelets, and other blood cells), extravasation, and proliferation. Cancer
can be associated with a prothrombotic state, increasing the risk of venous thromboembolic
events.1,2 Blood components have been implicated in playing a direct role in the
development of metastatic disease.3 Platelets may play a crucial role in the metastatic
process by affecting tumor cell arrest and adhesion at distant metastatic sites and can protect
tumor cells from immune attack.4 Gasic et al. demonstrated that lowering the platelet count
in mice resulted in decreased lung invasion after intravenous injection of tumor cell lines.5
Furthermore, antibodies directed against platelet antigens involved in tumor cell adhesion
decreased lung tumors in mice after intravenous administration.6-8 Preclinical models have
demonstrated that platelets together with tumor-secreted proteins influence the premetastatic
bone microenvironment and may promote the metastatic process.9 In vivo experiments have
shown that thrombin, a platelet activator, increases pulmonary metastasis, whereas a
thrombin inhibitor (r-hirudin), decreases melanoma pulmonary metastases.6,10-13 Clinically,
it has been shown that the addition of antiplatelet therapy to chemoradiotherapy in the
treatment of patients with small-cell lung cancer prolongs duration of remission and overall
survival.14
Studies that have used single-agent antiplatelet therapy in cancer have been promising. It is
of note that in the clinical management of cardiovascular diseases, dual-platelet therapies
have shown superior results. Circulating tumor cell (CTC) number has been associated with
overall and progression-free survival in women with metastatic breast cancer.15 To
investigate the effect of dual-antiplatelet therapy on CTCs in women with metastatic breast
cancer, a randomized controlled study was conducted using clopidogrel and aspirin to test




Women without actively progressing metastatic breast cancer who were not currently
receiving chemotherapy were eligible. Previous chemotherapy (adjuvant or metastatic) was
permitted. Concurrent endocrine therapy (for at least 2 months before enrollment),
bisphosphonate therapy, and/or trastuzumab were permitted. Patient care was directed by the
treating physician as clinically indicated. Eligible patients had an estimated survival ≥ 3
months, no platelet inhibitor therapy within 1 month of study, platelet count ≥ 100,000/mm3,
international normalized ratio within 0.81 to 1.20, and normal kidney and liver function by
institutional standard laboratory evaluation. Exclusion criteria were planned surgery, serious
bleeding disorders, history of significant bleeding related to peptic ulcer disease, standing
therapy with nonsteroidal antiinflammatory drugs or other platelet inhibitors, and
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anticoagulant therapy. The institutional review board approved the trial and written consent
was obtained from all patients before enrollment.
Patients were randomized to receive either clopidogrel (300 mg loading dose followed by 75
mg orally daily) and aspirin (325 mg orally daily) combination therapy, or no study
treatment. Initially, study therapy could be continued until tumor progression,
discontinuation of therapy because of an adverse event (AE), or withdrawal of consent. The
protocol was later amended to change the maximum study duration to 6 months.
Measurement of Circulating Tumor Cells
CTCs were measured at baseline, at 2 weeks and 4 weeks, and then monthly thereafter.
Patient blood samples were collected into 10-mL CellSave (Veridex, Raritan, NJ) tubes and
were stored at room temperature and subsequently processed within 72 to 96 hours of
collection. CTCs were isolated and measured using the CellSearch assay (Veridex, Raritan,
NJ). Samples were analyzed at Washington University with the exception of those collected
on Fridays, which were sent to Quest Diagnostics (Madison, NJ) to avoid a processing
delay. CTC numbers are reported per 7.5 mL of blood, and the limit of detection for the
CellSearch assay is 1 CTC/7.5 mL of blood. The technical details of CellSearch have
previously been described.16
Platelet Function Testing
To show study treatment pharmacologic efficacy, blood samples were collected for platelet
function testing using the VerifyNow system (Accumetrics, San Diego, CA) with P2Y12
and aspirin cartridges. VerifyNow is a turbidimetric-based optical detection system that
measures aspirin or clopidogrel inhibition of platelet aggregation.17 Citrated whole blood is
added to a test cartridge containing fibrinogen-coated beads and a platelet activator:
adenosine diphosphate (ADP) with prostaglandin E (to specifically activate the ADP P2Y12
receptor in the case of clopidogrel) or arachidonic acid (to synthesize thromboxane A2 in the
case of aspirin). Aggregation of activated platelets to fibrinogen-coated beads increases light
transmittance, which is reported in aspirin reaction units (ARUs) or P2Y12 reaction units
(PRUs). Lower ARU and PRU results are expected when patients take aspirin and
clopidogrel.17 Percent inhibition of platelet function by clopidogrel is determined by
dividing ADP-induced platelet aggregation (PRU) by thrombin-induced platelet aggregation.
Given the association of malignancy and hypercoagulability and the possible activating
effect of CTCs on platelets, the global hemostatic function was evaluated. Thrombin
generation, which measures the overall thrombogenic potential of the plasma sample, was
measured in patient plasma samples using the Calibrated Automated Thrombogram system
(CAT) (Diagnostica Stago, Parsippany, NJ) and the endogenous thrombin potential
percentage (ETP%) was calculated. ETP% is a global measure of the thrombogenic
potential, as opposed to the more traditional tests such as prothrombin time and the activated
partial thromboplastin time, which measure the activity of the extrinsic pathway of
coagulation or the intrinsic pathway, respectively. The CAT system is based on the
principles for automated thrombin generation measurement as described previously.18
Briefly, platelet-poor plasma is combined with an activator containing phospholipids and
human recombinant tissue factor. Generated thrombin cleaves a peptidyl substrate specific
for thrombin, which releases fluorescent 7-amino-4-methylcoumarin. Thrombin-generation
curves are plotted as thrombin concentration vs. time, with endogenous thrombin time (ETP)
being the area under the curve. ETP% is then generated by normalizing the experimental
sample with the ETP from a normal plasma sample.
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The primary end point was proportion of patients with detectable CTCs at 1 month. It has
been shown previously that more than 50% of patients with metastatic breast cancer have
detectable numbers of CTCs in the blood.15 Power analysis determined that 76 patients
would need to be enrolled to detect a 30% absolute reduction in patients with detectable
CTCs, assuming 50% prevalence of CTCs at baseline (80% power with 2-sided significance
level of .05). Statistics were generated using the statistical programs SPSS version 17.0.1
(SPSS, Inc, Chicago, IL) and Microsoft Excel (Microsoft Corp, Redmond, WA). Baseline
patient characteristics were compared between groups using the χ2 or Fisher exact test for
noncontinuous variables and the 2-sample t test for continuous variables. The proportion of
patients with detectable CTCs was compared at baseline, 2 weeks, and 1 month by the
Fisher exact test. Platelet function was compared between groups at different time points
using the Mann-Whitney test (2-tailed). Mean ETP% was compared between groups using
the 2-sample t test. ETP% was also correlated with CTC number (Pearson 2-tailed test).
Results
Patient Characteristics
Forty-eight patients were treated in our study, 24 of whom were randomized to treatment
and 24 to the control group. The patient flow chart is shown in Figure 1. Two patients in the
treatment arm dropped out at or before 1 month because of AEs. One of the AEs was
bleeding, which was thought to have resulted from treatment, and the other was back pain
deemed to be unlikely to be associated with treatment. Nineteen patients in the treatment
arm and 23 patients in the control arm were evaluable for the primary end point.
Patient baseline characteristics are shown in Table 1 and are well balanced overall between
groups. More than half of the patients had received 2 or more previous chemotherapy
regimens for metastatic disease, and more than 60% of patients had at least 2 sites of
metastatic disease. The mean age was 50.7 years in the treatment group and 58.4 years in the
control group. Across groups, baseline CTCs were ≥ 5 in only 13% of patients and were ≥ 1
in only 65% of the patients. The low percentage of patients with baseline detectable CTCs
prompted discontinuation of the study (because of futility) before all 76 patients were
enrolled. Baseline platelet counts and platelet function test results were no different between
groups.
Circulating Tumor Cell Responses
The proportion of patients with detectable CTCs (≥ 1 CTC) was calculated at baseline, 2
weeks, and one month, with the primary end point being at 1 month (Table 2). One quarter
of the patients in the observation arm had no CTCs present at baseline, whereas nearly one
half of those receiving the study therapy lacked baseline CTCs. Changes in CTC number
from baseline to 1 month were similar between treatment and control groups, with no
discernible trends in those with CTC-positive or CTC-negative status. The CTC status
remained fairly stable over time (Fig. 2) (6-month data are not shown), with no more than
25% of patients ever having more than 5 CTCs. Of the 4 patients who had early disease
progression before or shortly after the first month of study, CTC count increased by 1, 5, and
19 cells for each of 3 patients respectively, and decreased by 1 cell in 1 patient.
Platelet Function and Activation Responses
Platelet function response to aspirin and clopidogrel was assessed using specific platelet-
function tests for each drug. Suggesting compliance with study therapy, the data indicate
that the treatment group experienced a significant inhibition of platelet function at the 2- and
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4-week time points for both drugs (P < .001 for each) (Fig. 3). Both clopidogrel- and
aspirin-mediated platelet inhibition were similar across all time points for the control group.
These results demonstrate pharmacologic treatment effect in the aspirin/clopidogrel group
when compared with the control group.
The thrombogenic potential as assessed by ETP% did not correlate with CTC number (Table
3), and the mean ETP% was not different between treatment and control groups (data not
shown). ETP% did not correlate with treatment, age, estrogen receptor or HER2 status, or
number of metastatic sites (Table 3). These data suggest that this global marker of
coagulability potential, the ETP%, was not associated with CTC number or antiplatelet
treatment in patients with previously treated metastatic breast cancer.
Safety
There were no serious AEs (SAEs) related to bleeding or bruising in the treatment group.
There were 4 bleeding-related AEs and 15 AEs caused by bruising. The only SAEs that
were deemed to be possibly related to treatment were mucositis (grade 3 in 1 patient) and
grade 3 nausea, lymphopenia, and edema (all in a second patient). All other SAEs were
either deemed unrelated or unlikely to be related to treatment. Although a high incidence of
grade I/II bruising was noted, aspirin and clopidogrel were well tolerated in this population
of patients with metastatic breast cancer.
Discussion
Preclinical and epidemiologic data suggest that platelet activity may affect progression of
breast cancer. CTCs have been shown to correlate with disease outcomes in women with
breast cancer.15,19-21 This randomized phase II study of women with metastatic breast
cancer treated with dual-antiplatelet therapy or no treatment demonstrated a pharmacologic
effect with platelet inhibition that did not correspond with changes in CTCs at 1 month.
Similarly, thrombin generation, as measured by ETP%, did not correlate with changes in
CTCs at 1 month. There was no significant difference between patients who received
antiplatelet therapy and those who did not with respect to the proportion of detectable CTCs
at 1 month. Dual-antiplatelet therapy was well tolerated in patients with metastatic breast
cancer.
This clinical trial enrolled patients regardless of baseline CTC values. Only 13% of patients
had ≥ 5 CTCs at baseline and approximately one-third had no detectable CTCs. These low
CTC numbers were much lower than expected and may reflect the study population at large
and status of tumor control at point of study entry. The inclusion of patients who had no or
few CTCs at baseline limited the ability to distinguish patients who may have benefited
from antiplatelet therapy by the calculated 30% absolute reduction in CTCs at 1 month. The
study was closed before the planned enrollment of 76 participants because of the low
probability of achieving statistical significance with regard to the primary end point; hence,
these results cannot not be considered definitive. We performed a theoretical power
calculation to determine the number of patients needed if only patients with ≥ 5 CTCs were
included in the study. Two hundred eighty patients would need to be enrolled to detect a
10% absolute reduction (66% relative reduction) in patients who have ≥ 5 CTCs, assuming
the 15% prevalence of patients with CTCs ≥ 5 at baseline that we actually observed in this
study (80% power with 2-sided significance level of .05). Therefore, performing a similar
study that mandates higher CTC levels for patient inclusion would require significantly
larger enrollment numbers and may not be feasible.
This study was not designed to assess a rise in CTCs; however, the data from the 42
randomized patients who completed 1 month follow-up does not suggest that dual-
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antiplatelet therapy impedes the rate of CTC increase. The percentage of patients with ≥ 1
CTC remained relatively stable across time and study arm at 1 month. Again, this may
reflect the patient population and disease control, as well as the brief duration of the study.
Given the relatively homogeneous and low number of CTCs seen during our study, it is
possible that an anticancer response to anti-platelet therapy could have been observed if
other methods to measure tumor progression were incorporated into the study design (eg,
radiographic measurements, alternative tumor markers, or more sensitive CTC evaluation).
A recent report performed a comparison of CTC’s to carcinoembryonic antigen and cancer
antigen 15–3 in patients with metastatic breast cancer and found that the biochemical and
cellular biomarkers resulted in similar prediction of progression-free survival19. In our
study, radiographic assessments were not performed, and would not be expected to be
markedly changed in one month’s time. In hindsight, preselecting patients with high CTC
numbers may have increased the ability to observe a treatment effect, and the tests for global
hemostatic potential such as thrombin generation could be used as a screening tool to select
patients.
In the 42 patients who underwent serial assessment, it is unlikely that there would have been
genetic variability significant enough to have confounded the results. However, it is of note
that in preclinical studies, germline deletion of an important membrane-bound protein
involved in platelet aggregation, alphaII(b)beta3 integrin, significantly decreased the burden
of bone metastases in mice intravenously inoculated with melanoma cells.22 Likewise,
specific pharmacologic inhibition of alphaII(b)beta3 decreased metastases. Antibodies
blocking alpha(v)beta3 and alphaII(b)beta3 integrins have produced a reduction in tumor
size in mice.23 Additionally, the combined use of an apyrase/ADPase (APT102) and an
inhibitor of thromboxane synthesis (aspirin) resulted in significantly decreased breast cancer
and melanoma bone metastases in mice.24
Several epidemiologic studies have suggested a chemopreventive effect of aspirin on the
development of various cancers, particularly colorectal cancer, as well as cancers of the
stomach, breast, and lung.25 However, the results of clinical trials addressing platelet
inhibition as primary cancer prevention have been mixed.26-28 The Women’s Health Study,
which randomized 39,876 women to receive aspirin therapy or not showed a trend in
reduction of lung cancer but no effect for many of the other major cancers.27 Conversely,
pooled results from 2 smaller randomized trials showed a significant reduction in the risk of
colorectal cancer developing (hazard ratio, 0.74; confidence interval, 0.56-0.97; P = .02).28
In patients with colon cancer, adjuvant aspirin therapy failed to increase relapse-free
survival.29 Similarly, in patients with ovarian cancer, a derivative of dipyridamole, RA233,
did not show any benefit with respect to disease progression and overall survival when
combined with standard treatment.30
The preclinical and epidemiologic studies suggesting anticancer effects of antiplatelet
therapy were not refuted by this randomized phase II study. The negative results from this
translational randomized phase II study highlight the challenges of biomarker-driven trials
and provide data pertinent to designing future studies that may test platelet inhibitors in
patients with breast cancer. Future studies testing this hypothesis and the biological
characteristics of platelets affecting cancer outcomes remain warranted.
Conclusion
We conducted a randomized phase II study in patients with metastatic breast cancer to test
the hypothesis that antiplatelet therapy may decrease the number of CTCs. Despite adequate
platelet function inhibition in patients treated with aspirin and clopidogrel, no difference in
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the proportion of detectable CTCs was noted between the treatment and control groups at 1
month. Overall, aspirin and clopidogrel were relatively well tolerated, with no observed
SAEs from bleeding. This study helps to underscore the challenges of biomarker-driven
trials and can help inform the design of future studies aimed at assessing the role of
antiplatelet therapy in treating breast cancer.
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• Blockade of platelet activation and aggregation has been shown to inhibit
metastasis in preclinical models and is associated with cancer prevention in
humans.
• Currently, the role of antiplatelet therapy in treating and preventing breast
cancer remains undefined.
• In this study, we demonstrated that antiplatelet therapy did not have an apparent
effect on the number of CTCs in patients with metastatic breast cancer.
• CTC number was uniformly low in this study population of patients who had
relatively stable, heavily pretreated metastatic disease.
• Preselecting patients for studies with a high number of CTCs may help to
improve the utility of CTCs as a surrogate outcome measure in therapeutic
trials.
• Future studies investigating the utility of antiplatelet therapy in treating breast
cancer are needed.
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The CONSORT Trial Diagram Details the Flow of Patients Through Various Stages of the
Trial and the Reason for Patient Withdrawal up to and Just After 1 Month. Five Patients
Continued in the Trial Beyond 6 Months; However, Enrollment Time was Later Limited to 6
Months
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Percentage of Patients With a Given Number of Circulating Tumor Cells (CTCs) (Broken
Down by Categories) is Plotted Against Time. N = number of Patients With Valid Data at
Each Time Point. Patients Included in 2-Week and 4-Week Measurement Categories had
Measurements Performed Between 11 and 21 Days (Median 14 Days) and 21 and 49 Days
(Median 28 Days) After Starting Therapy, Respectively. (A) Percent of Patients With a
Given Circulating Tumor Cell (CTC) Number is Plotted vs. Time for Patients in the no-
Treatment (Control) Group. (B) Percent of Patients With a Given CTC Number is Plotted
vs. Time for Patients in the Treatment Group
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Mean Platelet Inhibition vs. Time is Plotted for Treatment and Control Groups for Baseline,
2-Week, and 4-Week Measurement Time Points for Both Aspirin-Mediated Platelet
Inhibition (A) and Clopidogrel-Mediated Platelet Inhibition (B). Patients Included in 2-
Week and 4-Week Measurement Categories had Measurements Performed Between 11 and
21 Days (Median 14 Days) and 21 and 49 Days (Median 28 Days), Respectively, After
Starting Therapy. Cases Were Excluded if Platelet Function Information was Missing for
any Time Point. Percent Platelet Inhibition a (P2Y12 Reaction Units)/(Thrombin Induced
Aggregation)
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Table 1
Baseline Patient Characteristics
Characteristic Control (n = 24) Treatment (n = 24) Valid n (Control) Valid n (Treatment)
Mean age, years 58.4 50.7 24 24
Baseline positive CTCs, no. (%) 18 (75) 12 (55) 24 22
Mean baseline platelet count, k/mm3 243.7 231.6 23 23
Mean ARU 585.4 604.8 23 20
Mean baseline clopidogrel platelet function, %
platelet inhibition
11.9 10.3 24 22
HER2+ no. (%) 10 (42) 8 (33) 24 24
ER+, no. (%) 13 (54) 15 (62) 24 24
Number of metastatic sites, no. (%) – – 24 24
 1 9 (38) 8 (33) – –
 2 7 (29) 7 (29)
 ≥ 3 8 (33) 9 (38)
Number of previous metastatic chemotherapy
regimens, no. (%)
– – 24 24
 0 4 (17) 6 (25) – –
 1 8 (33) 5 (21) – –
 2 6 (25) 4 (17) – –
 ≥ 3 6 (25) 9 (37) – –
Number of previous metastatic endocrine
therapies, no. (%)
– – 24 24
 0 11 (46) 8 (33) – –
 1 3 (12) 7 (29) – –
 ≥ 2 10 (42) 9 (38) – –
Concurrent trastuzumab use, no. (%) 9 (38) 5 (21) 24 24
Concurrent bisphosphonate use, no. (%) 9 (38) 12 (50) 24 24
Smoking, no. (%) 5 (22) 4 (17) 23 23
Abbreviations: ARU = aspirin reaction units; ER = estrogen receptor; HER = human epidermal growth factor.
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Table 2
Proportion of Patients with Detectable CTCs at 0 and 4 Weeks
Time of Determination Treatment Group Proportion + CTCs Proportion − CTCs P Value (2-tailed)
Baseline CTCs No treatment 18 of 24 = 75% 6/24 = 25% .21
Treatment 12 of 22 = 55% 10/22 = 45% –
4-Wk CTCs No treatment 15 of 23 = 65% 8/23 = 35% .75
Treatment 11 of 19 = 58% 8/19 = 42% –
Abbreviation: CTCs = circulating tumor cells.
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Table 3
Correlation of CTCs and ETP%
Variable Statistical Analysis ETP% Baseline ETP% 4 Weeks
CTC (baseline) Pearson correlation −0.163 −0.339
P value (2-tailed) 0.480 0.156
n 21 19
CTC (4 wk) Pearson correlation −0.008 −0.319
P value (2-tailed) 0.974 0.183
n 20 19
Treatment group Pearson correlation −0.279 −0.112
P value (2-tailed) 0.221 0.648
n 21 19
Age Pearson correlation −0.165 −0.023
P value (2-tailed) 0.474 0.925
n 21 19
HER2+ Pearson correlation −0.001 −0.046
P value (2-tailed) 0.996 −0.852
n 21 19
ER Pearson correlation 0.214 −0.027
P value (2-tailed) 0.351 0.914
n 21 19
Metastatic sites Pearson correlation −0.214 −0.079
P value (2-tailed) 0.353 −0.746
n 21 19
Abbreviations: ETP% = endogenous thrombin potential percentage; ER = estrogen receptor; HER = human epidermal growth factor.
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